| | | | EDITORIAL BY PATRICK ALEXANDRE
| Founder & CEO
| A Specialty Pharmaceutical Company Focused on Its Next Stage
| CROSSJECT continues its development trajectory with a clear ambition: to become a leading specialty pharmaceutical laboratory in emergency medicines for pre-hospital care. Our strategy remains focused on life-threatening emergency indications associated with active pharmaceutical ingredients whose benefits have already been demonstrated.
| We are currently advancing several key development programs. ZEPIZURE®, indicated for neurotoxic agent attacks and epileptic seizures, is entering a decisive stage prior to registration. ZENEO® Adrenaline, indicated for severe allergic reactions and anaphylactic shock, as well as ZENEO® Hydrocortisone, indicated for the treatment of acute adrenal insufficiency, are also continuing their advanced development.
| This dynamic is built on a key strength: the ZENEO® platform, whose clinical and technological performance has now been demonstrated. It enables us to anticipate shorter development cycles for future products, averaging three to five years. In the field of innovative medicines, this represents a major differentiating advantage.
| |
|
|
|
| | | | | | Angelo Collot’s Interview
| Production & Maintenance Manager at CROSSJECT
|
|
|
|
| To better understand the drivers of the production ramp-up, let us begin with the men and women working on the production lines. Who are they?
| CROSSJECT's production ramp-up is first and foremost built on the men and women who operate our industrial facilities every day. Our HR strategy is designed for the long term and is aligned with our operational timeline.
| Each new employee follows a structured skills development program, validated position by position and level by level, leading to the required qualifications. This skills development is supported by experienced Qualified Operators, who are themselves qualified to pass on the expertise required for each position. Recruiting individuals who are already integrated into our production system, particularly among our temporary employees, helps us achieve our recruitment objectives.
| Today, approximately forty people work across our production flow, including twenty-two production operators and three Production Supervisors. The teams are distributed between the Gray Glass manufacturing area, the Gray Pyrotechnics manufacturing area, and the Dijon manufacturing area. Each manufacturing area is supervised by a Production Supervisor.
| The tube pre-assembly activity in the new ZENEO® Nest manufacturing area in Dijon will further strengthen this organization, with a projected workforce of fifteen employees.
| How is the work organized?
| Our current organization is primarily based on a two-shift operation, with one morning shift and one afternoon shift, five days a week. This operating model corresponds to a production capacity of up to 300,000 units per year.
|
|
|
|
| | | | | Visit our production line by clicking on the thumbnail !
|
|
|
|
| | | | CROSSJECT at the Heart of the U.S. Pharmaceutical and Biotechnology Ecosystem
| From June 2 to 4, in Philadelphia, CROSSJECT participated in CPHI Americas, represented by Donald Zinn, Global Vice President, alongside leading companies from the pharmaceutical and biotechnology industries.
| This key event for the pharmaceutical and biotechnology ecosystem provided the Group with an opportunity to share its vision of needle-free injection technologies and their role in improving access to emergency medicines.
|
|
| | | CROSSJECT Highlights Its Innovation at VivaTech 2026 ,
| A flagship event for European innovation, VivaTech 2026 welcomed CROSSJECT from June 17 to 20 alongside the Bourgogne–Franche-Comté Region to represent the healthcare innovation developed in the region.
| On this occasion, CROSSJECT was featured on the BFM Business program “La France a tout pour réussir,” providing an opportunity to present its vision for faster access to emergency medicines and the importance of preparedness for situations where every minute counts.
|
|
| | | CROSSJECT Strengthens Its Strategic Presence in the United States
| CROSSJECT has joined the BioMaP Consortium, a U.S. network dedicated to health resilience and emergency preparedness.
| This milestone strengthens the Group's presence in the United States and highlights ZENEO®, its needle-free autoinjector designed for rapid and intuitive administration, while enabling the Company to anticipate future U.S. strategic stockpile funding priorities.
|
|
|
|
| | | You received this email because you subscribed to this newsletter.
| |
|
| | |
|
